Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common vitamin boost brain cancer treatment?

NCT ID NCT04677049

Terminated Disease control Sponsor: AHS Cancer Control Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding niacin (vitamin B3) to standard treatment (radiation and chemotherapy) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The trial has two phases: first, finding a safe dose of niacin, and second, checking if it improves survival at 6 months. About 59 adults aged 18-75 are being enrolled, but the trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Niacin (vitamin B3) controlled-release tablet
What this could lead to
If it works, this could point toward a way to improve survival for people with glioblastoma by adding a simple vitamin to standard therapy.
What could go wrong
This is an early-phase trial (phase I-II) with only 59 participants, so results may not apply broadly. The trial is currently suspended, and adding niacin may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE

Contacts and locations

Locations

  • Tom Baker Cancer Centre/Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 5G2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.